Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Effect of white blood count and absolute monocyte count on kidney function in chronic myelomonocytes leukemia (CMML)

Osama Batayneh, Deevyashali Parekh, Mahmoudreza Moein et al. Nov 03, 2025 pp. 7392-7392 10.1182/blood-2025-7392

Abstract Introduction Kidney injury is a common finding in patients with myeloproliferative neoplasms (MPN) such as CMML. Its etiology is mu...

CPX-351 versus venetoclax plus hypomethylating agents for newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis

Akihiro Miyashita, Abdulrahim Basendwah, Henri Fero et al. Nov 03, 2025 pp. 6987-6987 10.1182/blood-2025-6987

Abstract Introduction: Acute myeloid leukemia (AML) is one of the most common types of acute leukemia. Since the median age at diagnosis is...

Selective degradation of oncogenic signaling nodes by momelotinib-based protacs exerts potent anti-leukemic response in B-ALL, AML, and MF while sparing normal cells

Joshua Schwieterman, Sekhu Ansari, Mohammad Azam Nov 03, 2025 pp. 6108-6108 10.1182/blood-2025-6108

Abstract Despite notable advancements in developing targeted tyrosine kinase inhibitors (TKIs) therapy for hematologic malignancies such as...

Describing the feasibility and acceptability of an electronic adherence monitor to measure hydroxyurea adherence among youth with sickle cell disease

Nathaniel Goldfarb, Anyssa Young, Patrick McGann et al. Nov 03, 2025 pp. 4726-4726 10.1182/blood-2025-4726

Abstract Background: Prescription and claims data suggest hydroxyurea (HU) adherence is low among >50% of youth w...

Perioperative use of efanesoctocog alfa in Hemophilia A: A dual-center real-world study

Kadhim Al-Banaa, Terrence Sun, Doris Quon et al. Nov 03, 2025 pp. 3069-3069 10.1182/blood-2025-3069

Abstract Background: Persons with Hemophilia A (PWH) are at high risk of bleeding during and after surgery. Standard per...

MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation

Aaron Gillmor, Alfredo Rivas-Delgado, Manik Uppal et al. Nov 03, 2025 pp. 1766-1766 10.1182/blood-2025-1766

Abstract Background: Molecular classifications of diffuse large B-cell lymphoma (DLBCL) can identify patient groups that benefit from distin...

Integrative analysis of the interplay between peripheral immune landscape and leukemic blast adaptation in Acute Myeloid Leukemia

Ela Cerovska, Lukas Vacek, David Kundrat et al. Nov 03, 2025 pp. 3486-3486 10.1182/blood-2025-3486

Abstract Introduction and aims: With the rapid development of immunotherapeutic strategies in acute myeloid leukemia (AML), it has become in...

A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study

James England, Liying Zhang, Michelle Geddes et al. Nov 03, 2025 pp. 3862-3862 10.1182/blood-2025-3862

Abstract Background Myelodysplastic neoplasms (MDS) are a group of clonal malignancies of hematopoietic stem cells where progressive cytopeni...

Trends in chronic lymphocytic leukemia mortality among older adults with renal failure in the United States: A 25-year retrospective study.

Muhammad Shaheer Bin Faheem, Syed Tawassul Hassan, Sai Sushrutha Mudupula Vemula et al. Nov 03, 2025 pp. 8059-8059 10.1182/blood-2025-8059

Abstract Background: Renal failure is a frequent comorbidity in patients with chronic lymphocytic leukemia (CLL), contributing to poor outco...

DATA structuring and performance indicators for decision making in oncology and hematology

Bruno Pina, Edson Dias, Cinthya Da Silva et al. Nov 03, 2025 pp. 8209-8209 10.1182/blood-2025-8209

Abstract Background: Digital transformation in Brazilian hospitals has heightened the demand for high-quality data and strategic indicators...

Novel insights in therapeutic antibody therapies using advanced microscopy techniques

Christina Verbruggen, Patrick Eiring, Max Steinhardt et al. Nov 03, 2025 pp. 6111-6111 10.1182/blood-2025-6111

Abstract Introduction Immunotherapies have shown exceptional potential in achieving deep and durable remissions in Multiple Myeloma (MM). Ho...

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Gabriel Mannis, Nikolai Podoltsev, Deepa Jeyakumar et al. Nov 03, 2025 pp. 1645-1645 10.1182/blood-2025-1645

Abstract BACKGROUND The combination of venetoclax (VEN) with azacitidine (AZA) improves response rates and overall survival in newly diagnos...

Clinical use of genome-wide hi-c sequencing for assessment of structural variants in diffuse large B-cell lymphoma

Phillip Michaels, David Qualls, Anthony Schmitt et al. Nov 03, 2025 pp. 7862-7862 10.1182/blood-2025-7862

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive B-cell malignancy with heterogeneous genomic finding...

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

James Thompson, Lisa Rein, Michael Mauro et al. Nov 03, 2025 pp. 7311-7311 10.1182/blood-2025-7311

Abstract Background: Asciminib, an allosteric inhibitor of BCR::ABL1, has the potential to promote deeper molecular response (DMR) with redu...

Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study

Hishan Tharmaseelan, Janina Jablonski, Gundolf Schneider et al. Nov 03, 2025 pp. 3626-3626 10.1182/blood-2025-3626

Abstract Introduction: The benefit of antibiotic prophylaxis (ABP) during chemotherapy for cancer remains controversial. The growing resistan...

Real-world sequencing of anti-BCMA CAR T-cells and bispecific T-cell engagers in Relapsed/Refractory multiple myeloma: A multi-country analysis

Nicolas Blin, Christine Mai, Sigi Ertl et al. Nov 03, 2025 pp. 2287-2287 10.1182/blood-2025-2287

Abstract Background Multiple myeloma (MM) is the second most common hematologic malignancy, driven by uncontrolled plasm...

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes by age

Christina Poh, Francisco Hernandez-Ilizaliturri, Marek Trneny et al. Nov 03, 2025 pp. 3582-3582 10.1182/blood-2025-3582

Abstract Introduction: Incidence of follicular lymphoma (FL) increases with age and patients (pts) often relapse, requiring multiple lines of...

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Monzr M. Al Malki, Yi-Bin Chen, Tania Jain et al. Nov 03, 2025 pp. 2391-2391 10.1182/blood-2025-2391

Abstract Disease relapse is the leading cause of death after reduced-intensity conditioning (RIC)-based allogeneic hematopoietic cell transp...

Impact of pulmonary hypertension on in-hospital outcomes among patients hospitalized with multiple myeloma: A 2015–2022 national inpatient sample analysis

Faizan Ahmed, Haziq Ahmad, Haris Tahir et al. Nov 03, 2025 pp. 5805-5805 10.1182/blood-2025-5805

Abstract Background: Pulmonary hypertension (PH) is a serious disease that complicates a range of hematologic and cardiovascular disorders....

Real-world analysis of thromboprophylaxis use during autologous hematopoietic stem cell transplantation for lymphoma and multiple myeloma

Hannah Lee, Haein Kim, Brittany McGalliard et al. Nov 03, 2025 pp. 3124-3124 10.1182/blood-2025-3124

Abstract Background Patients with hematologic malignancy who undergo treatment become thrombocytopenic, and thromboprophylaxis (VTE ppx) is o...

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

Carla Isabel Borre, Mia Poleksic, Grant Spears et al. Nov 03, 2025 pp. 2999-2999 10.1182/blood-2025-2999

Abstract Introduction: Langerhans Cell Histiocytosis (LCH) is a rare histiocytic neoplasm, with approximately 90% of patients exhibiting alt...

ABC: Highly active and entirely calcineurin and m-TOR inhibitor-free gvhd prevention regimen

A Samer Al-Homsi, Stephanie Boisclair, Jaime Andres Suarez-Londono et al. Nov 03, 2025 pp. 2469-2469 10.1182/blood-2025-2469

Abstract Background: We previously reported results of posttransplant cyclophosphamide (PTCy) and bortezomib (CyBor) combination in graft-ve...

Outcomes with chimeric antigen receptor-t cell therapy in relapsed/refractory b-cell acute lymphoblastic leukemia: A systematic review and meta-analysis

Hafiz Muhammad Hannan Javed, Muhammad Kashif Amin, Hafsa Shahid et al. Nov 03, 2025 pp. 6875-6875 10.1182/blood-2025-6875

Abstract Introduction: B-cell acute lymphoblastic leukemia (B-ALL) has a very high relapse rate, with dismal median overall survival (mOS) a...

A genome-wide CRISPR activation screen identifies novel γ-globin regulators

Carea Mullin, Ginette Balbin-Cuesta, Greggory Myers et al. Nov 03, 2025 pp. 1136-1136 10.1182/blood-2025-1136

Abstract β-hemoglobinopathies, the most common monogenetic blood disorders, result from defective function or inadequate production of β-glo...

Cognitive and physical disability after traumatic brain injury in patients with sickle cell disease: A national cohort study from the all of us research program

Ektha Parchuri, Sohan Rao, Aqsa Owais et al. Nov 03, 2025 pp. 7965-7965 10.1182/blood-2025-7965

Abstract Background: Traumatic brain injury (TBI) in patients with sickle cell disease (SCD) has never been studied despite potential biolog...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page